Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia

ABSTRACT: We describe in vivo follow-up PET imaging and postmortem findings from an autosomal dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for the APOE3 Christchurch (APOE3ch) variant and was protected against Alzheimer's symptoms for almost three decades...

Full description

Autores:
Aguillón Niño, David Fernando
Quiroz Gaviria, Yakeel Tatiana
Baena, Ana
Sepulveda Falla, Diego Alonso
Lopera Restrepo, Francisco Javier
Almeida, María Camila
Boassa, Daniela
Acosta Uribe, Juliana
Vila Castelar, Clara
Ramírez Gómez, Liliana
Sánchez, Justin S.
Villalba Moreno, Nelson David
Littau, Jessica Lisa
Villegas Lanau, Carlos Andrés
Beach, Thomas G.
White 3rd, Charles L.
Ellisman, Mark
Krasemann, Susanne
Glatzel, Markus
Johnson, Keith A.
Sperling, Reisa A.
Reiman, Eric M.
Arboleda Velásquez, Joseph Fitzgerald
Kosik, Kenneth S.
Tipo de recurso:
Article of investigation
Fecha de publicación:
2022
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/42134
Acceso en línea:
https://hdl.handle.net/10495/42134
Palabra clave:
Alzheimer Disease
Enfermedad de Alzheimer
Amyloid beta-Peptides
Péptidos beta-Amiloides
Apolipoprotein E3
Apolipoproteína E3
Brain
Éncefalo
Homozygote
Homocigoto
Positron-Emission Tomography
Tomografía de Emisión de Positrones
tau Proteins
Proteínas tau
https://id.nlm.nih.gov/mesh/D000544
https://id.nlm.nih.gov/mesh/D016229
https://id.nlm.nih.gov/mesh/D053318
https://id.nlm.nih.gov/mesh/D001921
https://id.nlm.nih.gov/mesh/D006720
https://id.nlm.nih.gov/mesh/D049268
https://id.nlm.nih.gov/mesh/D016875
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
Description
Summary:ABSTRACT: We describe in vivo follow-up PET imaging and postmortem findings from an autosomal dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for the APOE3 Christchurch (APOE3ch) variant and was protected against Alzheimer's symptoms for almost three decades beyond the expected age of onset. We identified a distinct anatomical pattern of tau pathology with atypical accumulation in vivo and unusual postmortem regional distribution characterized by sparing in the frontal cortex and severe pathology in the occipital cortex. The frontal cortex and the hippocampus, less affected than the occipital cortex by tau pathology, contained Related Orphan Receptor B (RORB) positive neurons, homeostatic astrocytes and higher APOE expression. The occipital cortex, the only cortical region showing cerebral amyloid angiopathy (CAA), exhibited a distinctive chronic inflammatory microglial profile and lower APOE expression. Thus, the Christchurch variant may impact the distribution of tau pathology, modulate age at onset, severity, progression, and clinical presentation of ADAD, suggesting possible therapeutic strategies.